Brian McKelligon - 22 Feb 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
President and CEO, Director
Signature
/s/ Brian McKelligon
Issuer symbol
AKYA
Transactions as of
22 Feb 2024
Net transactions value
-$61,771
Form type
4
Filing time
01 Mar 2024, 21:21:06 UTC
Previous filing
20 Dec 2023
Next filing
22 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Award $0 +87,500 +57% $0.000000 240,063 22 Feb 2024 Direct F1, F2
transaction AKYA Common Stock Tax liability $49,416 -8,195 -3.4% $6.03 231,868 01 Mar 2024 Direct
transaction AKYA Common Stock Tax liability $12,355 -2,049 -1.9% $6.03 103,506 01 Mar 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Award $0 +175,000 $0.000000 175,000 22 Feb 2024 Common Stock 175,000 $5.35 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units shall vest in four (4) equal annual installments beginning on March 1, 2025, and annually thereafter until fully vested.
F2 Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
F3 Represents shares withheld to cover taxes on a restricted stock unit award previously granted February 23, 2023, which vest in four (4) equal annual installments beginning on March 1, 2024, and annually thereafter until fully vested.
F4 The options shall vest as follows: twenty-five percent (25%) shall vest on February 22, 2025 with the remainder vesting in 36 equal monthly installments beginning on March 22, 2025.